Prostate cancer cell lines

Details Prostate cancer cell lines Prostate cancer cell lines

2001-07-31

2004-08-17

Ungar, Susan (Department: 1642)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S366000, C435S371000, C435S173300, C424S093100, C424S093700

Reexamination Certificate

active

06777230

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to the fields of tissue culture and the treatment of human prostate cancer. More specifically, novel cell lines are provided which may be used to identify new biomarkers for prostate cancer progression.
BACKGROUND OF THE INVENTION
Several publications are referenced in this application by numerals in parentheses in order to more fully describe the state of the art to which this invention pertains. Full citations for these references are found at the end of the specification. The disclosure of each of these publications is incorporated by reference herein.
Prostatic carcinoma is the most common malignant disease among men in the Western world, and benign prostatic hyperplasia is the most prevalent benign disease (
1
). In Western countries, it is estimated that men have approximately a 10% chance of developing prostate cancer and a 3-4% chance of dying of causes directly related to carcinoma of the prostate. The annual incidence of prostate cancer continues to increase, and this type of cancer now accounts for approximately 28% of all cancers in American men, compared to 18% in 1980 (
1
).
NE cells are a normal component of both the developing and mature prostatic epithelium. They produce a variety of neurosecretory products that exhibit growth-promoting activities, including parathyroid hormone-related peptides, neurotensin, serotonin, calcitonin and bombesin-related peptides, which suggests that these cells function through endocrine/paracrine mechanisms to regulate normal development and secretory activity of the prostate (
2
).
In a normal prostate, NE cells are distributed throughout the tissue and are readily detectable by microscopy as morphologically heterogeneous cells with irregular neurite-like processes extending between epithelial cells which often protrude into the lumen. NE cells may also be detected in prostate tissue by the presence of dense secretory vesicles (
4
-
6
). In prostate tumor tissue, NE cells often localize in clusters which increase in number with tumor progression (
7
).
Androgen ablation therapy (also known as hormonal deprivation therapy) is a well-established form of treatment for various stages of prostate cancer, especially advanced stages of cancer. However, this treatment alone does not cure the disease. During the course of androgen ablation therapy, prostate cancer cells will eventually lose their dependency on androgen and become highly aggressive. The molecular mechanism underlying this transition remains largely unknown. One hypothesis is that androgen ablation may result in the expansion of NE cells which in turn enhances the aggressiveness of the surrounding tumor cells because the NE cells secrete growth and motility promoting factors (
3
-
5
,
8
-
10
).
Jiborn et al. (
11
) have shown that a marked increase in NE cell number is correlated with histopathologic tumor progression during androgen deprivation therapy, which suggests that resistance to hormonal therapy in prostate cancer may result from clonal proliferation of NE tumor cells. Interestingly, the proliferative index of neoplastic epithelial cells surrounding the NE cells is also often increased, which indicates that NE cells may act in a paracrine fashion by secreting growth-promoting factors, e.g., bombesin and neurotensin (
12
,
13
).
Additionally, Bonkhoff et al. (
14
) have indicated that increases in the number of NE cells in prostate carcinomas occur either as a result of an increase in the stem cell population, which gives rise to NE cells in basal cells of normal prostate tissue, or by a process of trans-differentiation from malignant epithelial cells. The latter process may occur as tumor cells undergo de-differentiation steps (which are hallmarks of malignancy) and then, under certain circumstances, such as stimulation by differentiation inducing factors, a fraction of multipotent cells enter into a trans-differentiation program which results in the increase in NE cell population. The NE cells that undergo trans-differentiation may also be involved in hormone-refractory growth of prostate cancer. Alternatively, the population of NE cells may merely correlate with tumor volume (
7
).
Although there are a number of hypotheses describing the mechanism by which the NE cell population increases in the prostate, all of the possible mechanisms suggest that NE cells are associated with tumor growth.
SUMMARY OF THE INVENTION
In accordance with the present invention, novel human prostate cancer-associated neuroendocrine (NE)-like cell lines have been established.
The NE-like cells were derived from androgen-responsive LNCaP human prostate cancer cells by long-term culturing in an androgen-depleted condition which resembles conditions similar to androgen ablation therapy. LNCaP cells were initially seeded in regular medium containing phenol-red-positive RPMI 1640 medium supplemented with 5% regular fetal bovine serum for three days. Individual cells were seeded in a steroid-reduced medium containing phenol red-free RPMI 1640 medium supplemented with 5% heat-inactivated, charcoal/dextran-treated fetal bovine serum. The cells were then permitted to continue propagating in the steroid-reduced medium until the cells grew as independent cell lines.
The NE-like cell lines of the invention may be used to advantage to identify new biomarkers for prostate cancer progression. The identification of such biomarkers facilitates the development of novel therapeutic strategies for the treatment and prevention of prostate cancer.


REFERENCES:
Embleton et al (Immunol Ser, 1984, 23:181-207).*
Hsu (in Tissue Culture Methods and Applications, Kruse and Patterson, Eds, 1973, Academic Press, NY, see abstract, p. 764).*
Mustafa Ozen et al, 1996, Intl J Oncology, 8(5): 883-888.*
Masters, J R et al, PNAS, USA, 2001, 98(14):8012-8017.*
Burchardt, T et al, 1999, J. Urol, 162(5): 1800-5.
Abrahamsson, P.-A, “Neuroendocrine cells in tumor growth of the prostate.” Endocrine-Related Cancer 6: 503-519 (1999).
Cox, Michael E., et al., “Activated 3′, 5′-Cyclic AMP-dependent Protein Kinase Is Sufficient to Induce Neuroendocrine-like Differentiation of the LNCaP Prostate Tumor Cell Line.” J Biol Chem, 275(18): 13812-13818 (2000).
Noordzij, M. A., et al., “Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate.” Urol Res 22: 333-341 (1995).
Abrahamsson, P.-A. and H. Lilja, “Partial Characterization of a Thyroid-Stimulating Hormone-like Peptide in Neuroendocrine Cells of the Human Prostate Gland.” The Prostate 14: 71-81 (1989).
Bonkhoff, Helmut, et al., “Relation of Endocrine-Paracrine Cells to Cell Proliferation in Normal, Hyperplastic, and Neoplastic Human Prostate,” The Prostate 19: 91-98.
P. J. Gkonos, et al., “Neuroendocrine peptides in the prostate,” Urol Res 23: 81-87 (1995).
Cussenot, Olivier, et al., “Evaluation and Clinical Value of Neuroendocrine Differentiation in Human Prostatic Tumors.” The Prostate Supplement 8: 43-51 (1998).
Ahlgren, G., et al., “Neuroendocrine Differentiation is not Prognostic of Failure After Radical Prostatectomy but Correlates with Tumor vol.” Urology 56(6): 1011-1015 (2000).
di Sant'Agnese, P. Anthony., “Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: A review of morphologic aspects.”Urology 51(Supplement 5A): 121-124 (1998).
di Sant'Agnese, P. Anthony., “Neuroendocrine Differentiation in Prostatic Carcinoma: An Update.” The Prostate Supplement 8: 74-79 (1998).
Jiborn, Thomas et al., “Neuroendocrine Differentiation in Prostatic Carcinoma During Hormonal Treatment.” Urology 51(4): 585-589 (1998).
Aprikian, Armen G., et al., “Neuroendocrine Differentiation and the Bombesin/Gastrin-Releasing Peptide Family of Neuropeptides in the Progression of Human Prostate Cancer.” The Prostate Supplement 8: 52-61 (1998).
Sehgal, Inder et al., “Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.” Proc. Natl. Acad. Sci. 91: 4673-4677 (1994).
Bonkhoff, Helmut and Klaus Remberger. “Differentiation Pathways a

Affiliated with

Also associated with

Rating

Prostate cancer cell lines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prostate cancer cell lines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate cancer cell lines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3347677